An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer

Grants

Funding Acknowledgements

M Michael has received funding from Pfizer Inc., Novartis, and Roche. He is also a member of the advisory board for Novartis, Pfizer Inc., Eli Lilly and Company, Ipsen Ltd and Sanofi Aventis. J Zalcberg has received research and/or travel support from Roche, Bayer Healthcare, Merck Serono, Amgen Inc., and Sanofi Aventis. He has also received honoraria from speaking and/or is a member of the advisory board from Roche, Bayer Healthcare, Amgen Inc., and Novartis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.